KR20210105343A - 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법 - Google Patents

폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법 Download PDF

Info

Publication number
KR20210105343A
KR20210105343A KR1020217016464A KR20217016464A KR20210105343A KR 20210105343 A KR20210105343 A KR 20210105343A KR 1020217016464 A KR1020217016464 A KR 1020217016464A KR 20217016464 A KR20217016464 A KR 20217016464A KR 20210105343 A KR20210105343 A KR 20210105343A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
diazaspiro
decane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217016464A
Other languages
English (en)
Korean (ko)
Inventor
스티브 링
마그달레나 알론소-갈리시아
토마스 팩
줄리 루르카
데이비드 카펜터
멜리사 로즈
Original Assignee
알타반트 사이언시스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알타반트 사이언시스 게엠베하 filed Critical 알타반트 사이언시스 게엠베하
Publication of KR20210105343A publication Critical patent/KR20210105343A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217016464A 2018-11-16 2019-11-15 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법 Ceased KR20210105343A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768575P 2018-11-16 2018-11-16
US62/768,575 2018-11-16
PCT/IB2019/001224 WO2020099926A1 (en) 2018-11-16 2019-11-15 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
KR20210105343A true KR20210105343A (ko) 2021-08-26

Family

ID=69182543

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217016464A Ceased KR20210105343A (ko) 2018-11-16 2019-11-15 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법

Country Status (8)

Country Link
US (2) US11413287B2 (https=)
EP (1) EP3880203A1 (https=)
JP (2) JP2022507533A (https=)
KR (1) KR20210105343A (https=)
CN (1) CN113242736A (https=)
AU (1) AU2019382168A1 (https=)
CA (1) CA3119909A1 (https=)
WO (1) WO2020099926A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11413287B2 (en) 2018-11-16 2022-08-16 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2020128614A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
MX2021009055A (es) 2019-01-30 2021-10-22 Altavant Sciences Gmbh Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo.
AU2020244278A1 (en) * 2019-03-15 2021-09-30 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875622B2 (en) 2007-07-11 2011-01-25 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
TW201245183A (en) * 2010-11-05 2012-11-16 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
UA119247C2 (uk) * 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9399741B2 (en) 2013-10-09 2016-07-26 Uop Llc Methods and apparatuses for desulfurizing hydrocarbon streams
CA3119912A1 (en) * 2018-11-14 2020-05-22 Altavant Sciences Gmbh A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
US11413287B2 (en) 2018-11-16 2022-08-16 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2020128614A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
WO2020128608A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
MX2021009055A (es) * 2019-01-30 2021-10-22 Altavant Sciences Gmbh Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo.
AU2020244278A1 (en) 2019-03-15 2021-09-30 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
CN115379825A (zh) 2020-01-31 2022-11-22 阿尔塔万特科学公司 用rodatristat治疗肺动脉高压的剂量和方法
US11937070B2 (en) 2021-07-01 2024-03-19 Tencent America LLC Layered description of space of interest
WO2023079486A1 (en) 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan

Also Published As

Publication number Publication date
US11911382B2 (en) 2024-02-27
US20230000866A1 (en) 2023-01-05
AU2019382168A1 (en) 2021-06-03
CN113242736A (zh) 2021-08-10
JP2022507533A (ja) 2022-01-18
US11413287B2 (en) 2022-08-16
WO2020099926A1 (en) 2020-05-22
CA3119909A1 (en) 2020-05-22
JP2024019691A (ja) 2024-02-09
US20200155552A1 (en) 2020-05-21
EP3880203A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
KR20210105343A (ko) 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법
TWI852999B (zh) 治療脂肪性肝病及/或脂肪性肝炎的方法
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
US20240024316A1 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
US20220096475A1 (en) Method for treating sarcoidosis-associated pulmonary hypertension
KR20010091012A (ko) 올티프라즈의 간섬유화 및 간경화 진행의 예방 및치료제로서의 용도 및 올티프라즈를 주성분으로 함유하는제약 조성물
CN113876775B (zh) 一种青藤碱或其药物可接受的盐作为治疗动脉性肺动脉高压药物的用途
JPH0152366B2 (https=)
HK40058221A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
EP0310259B1 (en) Eperisone as a hypotensive agent
CN108503651B (zh) 一种用于治疗脑卒中的螺环化合物
JP6976577B2 (ja) ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤
JP6875747B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
BE829197A (fr) Compositions anti-inflammatoires, leur preparation et leur utilisation
HK40054971B (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
JPWO2018012634A1 (ja) 不飽和複素５員環含有化合物を含有する肺高血圧症の予防又は治療剤
WO2004105753A1 (ja) 抗うつ剤または抗うつ用飲食品

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210528

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210916

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230831

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240308

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230831

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I